
Sign up to save your podcasts
Or


A meta-analysis of 11 studies encompassing more than 60,000 subjects finds that statins don’t lower all-cause mortality in people without cardiovascular disease. One editorialist calls the study, just published in the Archives of Internal Medicine, “the cleanest and most complete meta-analysis of pharmacological lipid lowering for primary prevention.”
One of the study’s principal authors, Kausik K. Ray, talked with us from London. I think you’ll find that listening in is worth your time.
Interview-related links:
News-related links:
That’s the question asked in an intriguing essay — by a radiologist — released online in the New England Journal of Medicine. We have her as our guest this week.
Feedback, please! You can comment here or by emailing me at [email protected] — or better still, call 1-617-440-4374.
Interview-related links:
News-related links:
A JAMA paper suggests that in all but the most severe exacerbations of COPD, it’s best to start off with low-dose oral corticosteroids rather than the higher-dose intravenous treatment that, contrary to guideline recommendations, almost everyone now gets. Our conversation this week is with the study’s first author, Dr. Peter Lindenauer.
Visit the Journal Watch website at http://jwatch.org for a comprehensive look at new medical research, with comments from our experts.
Interview-related links:
News-related links:
We talk with a Danish researcher, Emil Fosbøl, whose team estimated the risks of cardiovascular events caused by NSAID use in healthy people.
Your feedback is always welcomed and encouraged. Please drop me a note ([email protected]) or call in a comment to 1-617-440-4374. I’m eager to act on your suggestions.
The interview-related link:
News-related links:
Canadian researchers took the approach of using low doses of rosiglitazone and metformin in combination. They compared that treatment with placebo in a small group of 200 patients with impaired glucose tolerance. Those receiving treatment had a much lower risk of developing type 2 diabetes over the ensuing 4 years of follow-up.
The results aren’t anywhere near ready for allowing clinical use, but they at least move us a bit through the fog. Our conversation this week is with Bernard Zinman, the principal author of the study, just published in the Lancet.
News-related link: First Watch coverage of BMJ study on hormone-replacement therapy
Glasses — when did you start wearing them? They serve to help us do more than just read the newspaper, according to our conversational guest today. Prof. Stephen Lord of Sydney’s Prince of Wales Medical Research Institute and his coauthors write in BMJ this week about trying to encourage elderly wearers of multifocal lenses to use single-focus lenses when they walk outside, where the terrain is unfamiliar. The results are practical, and the discussion about them (Prof. Lord’s side of it, that is) enlightening.
Give us a call at 617-440-4374.
This week’s conversation-related link:
This week’s news-related links:
The New England Journal of Medicine carries several studies comparing the long-term outcomes of endovascular versus open repair of abdominal aortic aneurysms. Tying all those studies together is an editorial by Dr. K. Craig Kent of the University of Wisconsin. We’ve got him as our guest this week. Have a listen.
Interview-related links:
News-related links
Dr. Robert Centor of the University of Alabama at Birmingham believes that the paradigm for treating pharyngitis in adolescents and young adults must change. Listen to our conversation and hear why.
Here are this week’s links:
Interview-related links:
News-related links:
Why wouldn’t you want your hospital to lower its rate of early readmissions for heart failure by 15%? We talk with Dr. Adrian Hernandez about his examination of Medicare data from over 200 hospitals, how the hospitals vary widely in the rates at which their patients are followed up within a week of discharge for heart failure, and what that means for readmission rates. Hint: hospitals with more efficient follow-up have lower readmission rates. Listen in to our conversation.
Interview-related link:
News-related links:
A surprise finding: homocysteine is supposed to be a factor in vascular inflammation, but lowering hyperhomocysteinemia in patients with diabetic nephropathy actually accelerated the decline of their GFRs. What gives?
We have a conversation with Dr. J. David Spence, whose results were just published in JAMA.
Interview-related link:
News-related links: